Characterization and prediction of adverse events from intensive chronic heart failure management and effect on quality of life: Results from the pro-B-type natriuretic peptide outpatient-tailored chronic heart failure therapy (PROTECT) study

Journal of Cardiac Failure

Volumn 21, Issue 1, 2015, Pages 9-15

  Gandhi, Parul U ^a   Szymonifka, Jackie ^a   Motiwala, Shweta R ^b   Belcher, Arianna M ^a   Januzzi, James L ^a   Gaggin, Hanna K ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Heart failure; medication; natriuretic peptides

Indexed keywords

ACETYLSALICYLIC ACID; ALDOSTERONE ANTAGONIST; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHLORIDE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOOP DIURETIC AGENT; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; CARDIOVASCULAR AGENT; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

ACUTE KIDNEY FAILURE; ADULT; ADVERSE OUTCOME; ARTICLE; CHLORIDE BLOOD LEVEL; DIZZINESS; DRUG DOSE INCREASE; ECHOCARDIOGRAPHY; FAINTNESS; FEMALE; FOLLOW UP; HEALTH CARE QUALITY; HEART FAILURE; HUMAN; HYPERKALEMIA; HYPOKALEMIA; HYPOTENSION; INTENSIVE CARE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PREDICTION; QUALITY OF LIFE; AGED; BLOOD; CHEMICALLY INDUCED; CHRONIC DISEASE; CONTROLLED STUDY; DISEASE MANAGEMENT; MIDDLE AGED; PREDICTIVE VALUE; PROSPECTIVE STUDY; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RENAL INSUFFICIENCY; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CARDIOVASCULAR AGENTS; CHRONIC DISEASE; DISEASE MANAGEMENT; DIZZINESS; FEMALE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; QUALITY OF LIFE; QUESTIONNAIRES; RENAL INSUFFICIENCY; TREATMENT OUTCOME;

EID: 84919681427     PISSN: 10719164     EISSN: 15328414     Source Type: Journal    
DOI: 10.1016/j.cardfail.2014.10.008     Document Type: Article

References (19)

1. M.A. Steinman, L. Dimaano, C.A. Peterson, P.A. Heidenreich, S.J. Knight, and K.Z. Fung Reasons for not prescribing guideline-recommended medications to adults with heart failure Med Care 51 2013 901 907
2. M.S. Kiernan, D. Wentworth, G. Francis, F.A. Martinez, K. Dickstein, and M. Komajda Predicting adverse events during angiotensin receptor blocker treatment in heart failure: results from the HEAAL trial Eur J Heart Fail 14 2012 1401 1409
3. A.S. Desai, K. Swedberg, J.J. McMurray, C.B. Granger, S. Yusuf, and J.B. Young Incidence and predictors of hyperkalemia in patients with heart failure: an analysis of the CHARM Program J Am Coll Cardiol 50 2007 1959 1966
4. E.L. Knight, R.J. Glynn, K.M. McIntyre, H. Mogun, and J. Avorn Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: results from the studies of left ventricular dysfunction (SOLVD) Am Heart J 138 5 Pt 1 1999 849 855
5. B. Pitt, G. Bakris, L.M. Ruilope, L. DiCarlo, R. Mukherjee EPHESUS Investigators Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) Circulation 118 2008 1643 1650
6. G. Savarese, B. Trimarco, S. Dellegrottaglie, M. Prastaro, F. Gambardella, and G. Rengo Natriuretic peptide-guided therapy in chronic heart failure: a meta-analysis of 2,686 patients in 12 randomized trials PLoS One 8 2013 e58287
7. R.W. Troughton, C.M. Frampton, H.P. Brunner-La Rocca, M. Pfisterer, L.W. Eurlings, and H. Erntell Effect of B-type natriuretic peptide-guided treatment of chronic heart failure on total mortality and hospitalization: an individual patient meta-analysis Eur Heart J 35 2014 1559 1567
8. A. Bhardwaj, S.U. Rehman, A. Mohammed, A.L. Baggish, S.A. Moore, and J.L. Januzzi Jr. Design and methods of the Pro-B Type Natriuretic Peptide Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) study Am Heart J 159 2010 532 538.e1
9. J.L. Januzzi Jr., S.U. Rehman, A.A. Mohammed, A. Bhardwaj, L. Barajas, and J. Barajas Use of amino-terminal pro-B-type natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular systolic dysfunction J Am Coll Cardiol 58 2011 1881 1889
10. T.S. Rector, S.H. Kubo, and J.N. Cohn Patients self-assessment of their congestive heart failure: content, reliability and validity of a new measure, the Minnesota Living With Heart Failure questionnaire Heart Fail 3 1987 198 209
11. H.K. Gaggin, Q.A. Truong, S.U. Rehman, A.A. Mohammed, A. Bhardwaj, and K.A. Parks Characterization and prediction of natriuretic peptide "nonresponse" during heart failure management: results from the ProBNP Outpatient Tailored Chronic Heart Failure (PROTECT) and the NT-proBNP-Assisted Treatment to Lessen Serial Cardiac Readmissions and Death (BATTLESCARRED) study Congest Heart Fail 19 2013 135 142
12. E.A. Stead Jr. Renal factor in congestive heart failure Circulation 3 1951 294 299
13. A.J. Peixoto, and R.J. Alpern Treatment of severe metabolic alkalosis in a patient with congestive heart failure Am J Kidney Dis 61 2013 822 827
14. W.C. Levy, D. Mozaffarian, D.T. Linker, S.C. Sutradhar, S.D. Anker, and A.B. Cropp The Seattle Heart Failure Model: prediction of survival in heart failure Circulation 113 2006 1424 1433
15. K. Chatterjee The fear of beta-blocker therapy in heart failure: time to forget Arch Intern Med 164 2004 1370 1371
16. D.T. Ko, P.R. Hebert, C.S. Coffey, J.P. Curtis, J.M. Foody, and A. Sedrakyan Adverse effects of beta-blocker therapy for patients with heart failure: a quantitative overview of randomized trials Arch Intern Med 164 2004 1389 1394
17. H.K. Gaggin, S. Motiwala, A. Bhardwaj, K.A. Parks, and J.L. Januzzi Jr. Soluble concentrations of the interleukin receptor family member ST2 and beta-blocker therapy in chronic heart failure Circ Heart Fail 6 2013 1206 1213
18. G.C. Fonarow, N.M. Albert, A.B. Curtis, W.G. Stough, M. Gheorghiade, and J.T. Heywood Improving evidence-based care for heart failure in outpatient cardiology practices: primary results of the Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting (IMPROVE HF) Circulation 122 2010 585 596
19. S. Sanders-van Wijk, S. Muzzarelli, M. Neuhaus, S. Kiencke, M. Maeder, and W. Estlinbaum Safety and tolerability of intensified, N-terminal pro brain natriuretic peptide-guided compared with standard medical therapy in elderly patients with congestive heart failure: results from TIME-CHF Eur J Heart Fail 15 2013 910 918